Zolpidem for insomnia

Bibliography

• Langtry HD, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40:291-313
   PubMed Web of Science ®Google Scholar
• Hoehns JD, Perry PJ. Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 1993;12:814-28
   PubMedGoogle Scholar
• Roth T, Puech AJ, Paiva T. Zolpidem–place in therapy. In: Freeman H, Puech AJ, Roth T, editors. Zolpidem: An Update of its Pharmacological Properties and Thereapeutic Place in the Management of Insomnia. Elsevier; Paris: 1996. p. 215-30
   Google Scholar
• Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000;59:865-89
   PubMed Web of Science ®Google Scholar
• Harrison TS, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 2005;19:65-89
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. Pharmacokinetic determinants of the clinical effects of benzodiazepine agonist hypnotics. In: Monti JM, Pandi-Perumal S, Mohler H, editors. GABA and Sleep. Springer; Basel: 2010. p. 95-118
   Google Scholar
• Greenblatt DJ. Sleep and geriatric psychopharmacology. In: Pandi-Perumal SR, Verster JC, Monti JM, Lader MH, Langer SZ, editors. Sleep Disorders: Diagnosis and Therapeutics. Informa Healthcare; London: 2008. p. 163-73
   Google Scholar
• Greenblatt DJ, Harmatz JS, Shader RI. Psychotropic drug prescribing in the United States: extent, costs, and expenditures. J Clin Psychopharmacol 2011;31:1-3
   PubMed Web of Science ®Google Scholar
• Sieghart W. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol Rev 1995;47:181-234
   PubMed Web of Science ®Google Scholar
• Sanger DJ. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004;18(Suppl 1):9-15
   PubMed Web of Science ®Google Scholar
• Crestani F, Martin JR, Mohler H, Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 2000;131:1251-4
   PubMed Web of Science ®Google Scholar
• Patat A, Naef MM, Van Gessel E, Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic. Clin Pharmacol Ther 1994;56:430-6
   PubMed Web of Science ®Google Scholar
• Byrnes JJ, Greenblatt DJ, Miller LG. Benzodiazepine receptor binding of non-benzodiazepines in vivo: alpidem, zolpidem, and zopiclone. Brain Res Bull 1992;29:905-8
   PubMed Web of Science ®Google Scholar
• Sanger DJ, Benavides J, Perrault G, Recent developments in the behavioral pharmacology of benzodiazepine receptors: evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994;18:355-72
   PubMed Web of Science ®Google Scholar
• Griebel G, Perrault G, Letang V, New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes. Psychopharmacology (Berl) 1999;146:205-13
   PubMed Web of Science ®Google Scholar
• Rudolph U, Crestani F, Möhler H. GABAA receptor subtypes: Dissecting their pharmacological functions. Trends Pharmacol Sci 2001;22:188-94
   PubMed Web of Science ®Google Scholar
• Sanna E, Busonero F, Talani G, Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 2002;451:103-10
   PubMed Web of Science ®Google Scholar
• Olsen RW, Sieghart W. GABAA receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 2009;56:141-8
   PubMed Web of Science ®Google Scholar
• Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov 2011;10:685-97
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol 2009;24:1601-12
   PubMed Web of Science ®Google Scholar
• Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines: a review. Pharmacol Biochem Behav 1998;61:253-69
   PubMed Web of Science ®Google Scholar
• Lobo BL, Greene WL. Zolpidem: distinct from triazolam? Ann Pharmacother 1997;31:625-32
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Granda BW, Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 1999;48:89-97
   PubMed Web of Science ®Google Scholar
• Durand A, Thénot JP, Bianchetti G, Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab Rev 1992;24:239-166
   PubMed Web of Science ®Google Scholar
• Patat A, Trocherie S, Thebault JJ, EEG profile of intravenous zolpidem in healthy volunteers. Psychopharmacology (Berl) 1994;114:138-46
   PubMed Web of Science ®Google Scholar
• Salvá P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 1995;29:142-53
   PubMed Web of Science ®Google Scholar
• de Haas SL, Schoemaker RC, van Gerven JM, Pharmacokinetics, pharmacodynamics and the pharmacokinetic/pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol 2010;24:1619-29
   PubMed Web of Science ®Google Scholar
• Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004;43:227-38
   PubMed Web of Science ®Google Scholar
• Friedman H, Greenblatt DJ, Burstein ES, Population study of triazolam pharmacokinetics. Br J Clin Pharmacol 1986;22:639-42
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, Friedman H, A large-sample study of diazepam pharmacokinetics. Ther Drug Monit 1989;11:652-7
   PubMed Web of Science ®Google Scholar
• Olubodun JO, Ochs HR, von Moltke LL, Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol 2003;56:297-304
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, von Moltke LL, Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther 2000;293:435-43
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 2008;48:1350-5
   PubMed Web of Science ®Google Scholar
• Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005;44:33-60
   PubMed Web of Science ®Google Scholar
• Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 2007;82:87-96
   PubMed Web of Science ®Google Scholar
• McLean A, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004;56:163-84
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations. Clin Pharmacokinet 1991;21:165-77; 262-273
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. Preparation of scientific reports on pharmacokinetic drug interaction studies. J Clin Psychopharmacol 2008;28:369-73
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL. Clinical studies of drug-drug interactions: design and interpretation. In: Pang KS, Rodrigues AD, Peter RM, editors. Enzyme and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges. Springer; New York: 2010. p. 625-49
   Google Scholar
• von Moltke LL, Greenblatt DJ. Clinical drug interactions due to metabolic inhibition: Prediction, assessment, and interpretation. In: Lu C, Li AP, editors. Enzyme Inhibition in Drug Discovery and Development. Hoboken NJ, John Wiley & Sons; 2010. p. 533-47
   Google Scholar
• Greenblatt DJ. Introduction to drug-drug interactions. In: Piscitelli SC, Rodvold KA, Pai MP, editors. Drug Interactions in Infectious Diseases. 3rd edition. Human Press; New York: 2011. p. 1-10
   Google Scholar
• Olubodun JO, Ochs HR, Trüten V, Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. J Clin Pharmacol 2002;42:1142-6
   PubMed Web of Science ®Google Scholar
• Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 2003;17:513-32
   PubMed Web of Science ®Google Scholar
• Vlase L, Popa A, Neag M, Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. Eur J Drug Metab Pharmacokinet 2011;35:83-7
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 2000;24:129-36
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Weemhoff JL, Perloff MD, Effect of zolpidem on human Cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos 2002;23:361-7
   PubMed Web of Science ®Google Scholar
• Polasek TM, Sadagopal JS, Elliot DJ, In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. Eur J Clin Pharmacol 2010;66:275-83
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, von Moltke LL, Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998;64:553-61
   PubMed Web of Science ®Google Scholar
• Shader RI, Dreyfuss D, Gerrein JR, Sedative effects and impaired learning and recall following single oral doses of lorazepam. Clin Pharmacol Ther 1986;39:526-9
   PubMed Web of Science ®Google Scholar
• Otmani S, Demazieres A, Staner C, Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol 2008;23:693-705
   PubMed Web of Science ®Google Scholar
• Balkin TJ, O'Donnell VM, Wesensten N, Comparison of the daytime sleep and performance effects of zolpidem versus triazolam. Psychopharmacology (Berl) 1992;107:83-8
   PubMed Web of Science ®Google Scholar
• Roehrs T, Merlotti L, Zorick F, Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berl) 1994;116:130-4
   PubMed Web of Science ®Google Scholar
• Rush CR and Griffiths RR. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 1996;16:146-57
   PubMed Web of Science ®Google Scholar
• Rush CR, Armstrong DL, Ali JA, Benzodiazepine-receptor ligands in humans: acute performance-impairing, subject-rated and observer-rated effects. J Clin Psychopharmacol 1998;18:154-66
   PubMed Web of Science ®Google Scholar
• Mintzer MZ, Frey JM, Griffiths RR. Zolpidem is differentiated from triazolam in humans using a three-response drug discrimination procedure. Behav Pharmacol 1998;9:545-59
   PubMed Web of Science ®Google Scholar
• Troy SM, Lucki I, Unruh MA, Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol 2000;20:328-37
   PubMed Web of Science ®Google Scholar
• Priest R, Terzano M, Parrino L, Efficacy of zolpidem in insomnia. Eur Psychiatry 1997;12(Suppl 1):5-14
   PubMedGoogle Scholar
• Nowell PD, Mazumdar S, Buysse DJ, Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. J Am Med Assoc 1997;278:2170-6
   PubMed Web of Science ®Google Scholar
• Dündar Y, Dodd S, Strobl J, Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol 2004;19:305-22
   PubMed Web of Science ®Google Scholar
• Buscemi N, Vandermeer B, Friesen C, The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007;22:1335-50
   PubMed Web of Science ®Google Scholar
• Glass J, Lanctot KL, Herrmann N, Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. Br Med J 2005;331:1169
   PubMed Web of Science ®Google Scholar
• Dolder C, Nelson M, McKinsey J. Use of non-benzodiazepine hypnotics in the elderly: are all agents the same? CNS Drugs 2007;21:389-405
   PubMed Web of Science ®Google Scholar
• Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev 2009;13:265-74
   PubMed Web of Science ®Google Scholar
• Roehrs TA, Randall S, Harris E, Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study. Sleep 2011;34:207-12
   PubMed Web of Science ®Google Scholar
• Undén M, Roth-Schechter B. Next day effects after nighttime treatment with zolpidem: a review. Eur Psychiatry 1996;11(Suppl 1):21s-30s
   PubMedGoogle Scholar
• Allain H, Monti J. General safety profile of zolpidem: safety in elderly, overdose and rebound effects. Eur Psychiatry 1997;12(Suppl 1):21-9
   PubMedGoogle Scholar
• Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol 1998;13:157-67
   PubMed Web of Science ®Google Scholar
• Darcourt G, Pringuey D, Sallière D, The safety and tolerability of zolpidem: an update. J Psychopharmacol 1999;13:81-93
   PubMed Web of Science ®Google Scholar
• Zammit G. Comparative tolerability of newer agents for insomnia. Drug Saf 2009;32:735-48
   PubMed Web of Science ®Google Scholar
• Monti JM, Attali P, Monti D, Zolpidem and rebound insomnia–a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994;27:166-75
   PubMed Web of Science ®Google Scholar
• Ware JC, Walsh JK, Scharf MB, Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol 1997;20:116-25
   PubMed Web of Science ®Google Scholar
• Lahmeyer H, Wilcox CS, Kann J, Subjective efficacy of zolpidem in outpatients with chronic insomnia: a double-blind comparison with placebo. Clin Drug Investig 1997;13:134-44
   Web of Science ®Google Scholar
• Roehrs TA, Randall S, Harris E, Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Hajak G, Hedner J, Eglin M, A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients. Sleep Med 2009;10:705-12
   PubMed Web of Science ®Google Scholar
• Ator NA. Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectr 2005;10:31-9
   PubMed Web of Science ®Google Scholar
• Rowlett JK, Platt DM, Lelas S, Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. PNAS 2005;102:915-20
   PubMed Web of Science ®Google Scholar
• Follesa P, Mancuso L, Biggio F, Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long-term exposure to, zaleplon or zolpidem. Neuropharmacology 2002;42:191-8
   PubMed Web of Science ®Google Scholar
• Evans SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990;255:1246-54
   PubMed Web of Science ®Google Scholar
• Jaffe JH, Bloor R, Crome I, A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction 2004;99:165-73
   PubMed Web of Science ®Google Scholar
• Hajak G, Müller WE, Wittchen HU, Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003;98:1371-8
   PubMed Web of Science ®Google Scholar
• Victorri-Vigneau C, Dailly E, Veyrac G, Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 2007;64:198-209
   PubMed Web of Science ®Google Scholar
• Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998;20(Suppl C):C40-4
   PubMed Web of Science ®Google Scholar
• Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging 1998;12:43-53
   PubMed Web of Science ®Google Scholar
• Tamblyn R, Abrahamowicz M, du Berger R, A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005;53:233-41
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Wang PS. Claims data studies of sedative-hypnotics and hip fractures in older people: exploring residual confounding using survey information. J Am Geriatr Soc 2005;53:948-54
   PubMed Web of Science ®Google Scholar
• Allain H, Bentue-Ferrer D, Polard E, Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 2005;22:749-65
   PubMed Web of Science ®Google Scholar
• Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004;18:297-328
   PubMed Web of Science ®Google Scholar
• Frey DJ, Ortega JD, Wiseman C, Influence of zolpidem and sleep inertia on balance and cognition during nighttime awakening: a randomized placebo-controlled trial. J Am Geriatr Soc 2011;59:73-81
   PubMed Web of Science ®Google Scholar
• Mets MA, Volkerts ER, Olivier B, Effect of hypnotic drugs on body balance and standing steadiness. Sleep Med Rev 2010;14:259-67
   PubMed Web of Science ®Google Scholar
• Wang PS, Bohn RL, Glynn RJ, Zolpidem use and hip fractures in older people. J Am Geriatr Soc 2001;49:1685-90
   PubMed Web of Science ®Google Scholar
• Zint K, Haefeli WE, Glynn RJ, Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf 2010;19:1248-55
   PubMed Web of Science ®Google Scholar
• Chang CM, Chen MJ, Tsai CY, Medical conditions and medications as risk factors of falls in the inpatient older people: a case-control study. Int J Geriatr Psychiatry 2011;26:602-7
   PubMed Web of Science ®Google Scholar
• Finkle WD, Der JS, Greenland S, Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults. J Am Geriatr Soc 2011;59:1883-90
   PubMed Web of Science ®Google Scholar
• Rhalimi M, Helou R, Jaecker P. Medication use and increased risk of falls in hospitalized elderly patients: a retrospective, case-control study. Drugs Aging 2009;26:847-52
   PubMed Web of Science ®Google Scholar
• Avidan AY, Fries BE, James ML, Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 2005;53:955-62
   PubMed Web of Science ®Google Scholar
• Dubois S, Bedard M, Weaver B. The impact of benzodiazepines on safe driving. Traffic Inj Prev 2008;9:404-13
   PubMed Web of Science ®Google Scholar
• Neutel I. Benzodiazepine-related traffic accidents in young and elderly drivers. Hum Psychopharmacol Clin Exp 1998;13:S115-23
   Web of Science ®Google Scholar
• Orriols L, Philip P, Moore N, Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther 2011;89:595-601
   PubMed Web of Science ®Google Scholar
• Smink BE, Lusthof KJ, de Gier JJ, The relation between the blood benzodiazepine concentration and performance in suspected impaired drivers. J Forensic Leg Med 2008;15:483-8
   PubMedGoogle Scholar
• Jones AW, Holmgren A, Kugelberg FC. Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results. Ther Drug Monit 2007;29:248-60
   PubMed Web of Science ®Google Scholar
• Gustavsen I, Al-Sammurraie M, Morland J, Impairment related to blood drug concentrations of zopiclone and zolpidem compared to alcohol in apprehended drivers. Accid Anal Prev 2009;41:462-6
   PubMed Web of Science ®Google Scholar
• Yang YH, Lai JN, Lee CH, Increased risk of hospitalization related to motor vehicle accidents among people taking zolpidem: a case-crossover study. J Epidemiol 2011;21:37-43
   PubMed Web of Science ®Google Scholar
• Gustavsen I, Bramness JG, Skurtveit S, Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med 2008;9:818-22
   PubMed Web of Science ®Google Scholar
• Philip P, Sagaspe P, Taillard J, Fatigue, sleepiness, and performance in simulated versus real driving conditions. Sleep 2005;28:1511-16
   PubMed Web of Science ®Google Scholar
• Philip P, Sagaspe P, Taillard J, Fatigue, sleep restriction, and performance in automobile drivers: a controlled study in a natural environment. Sleep 2003;26:277-80
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Verster JC, Kayumov L, Sleep disorders, sleepiness and traffic safety: a public health menace. Braz J Med Biol Res 2006;39:863-71
   PubMed Web of Science ®Google Scholar
• Sagberg F. Road accidents caused by drivers falling asleep. Accid Anal Prev 1999;31:639-49
   PubMed Web of Science ®Google Scholar
• Powell NB, Schechtman KB, Riley RW, The road to danger: the comparative risks of driving while sleepy. Laryngoscope 2001;111:887-93
   PubMed Web of Science ®Google Scholar
• Connor J, Norton R, Ameratunga S, Driver sleepiness and risk of serious injury to car occupants: population based case control study. Br Med J 2002;324:1125
   PubMed Web of Science ®Google Scholar
• Staner L, Ertle S, Boeijinga P, Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology (Berl) 2005;181:790-8
   PubMed Web of Science ®Google Scholar
• Verster JC, Veldhuijzen DS, Volkerts ER. Residual effects of sleep medication on driving ability. Sleep Med Rev 2004;8:309-25
   PubMed Web of Science ®Google Scholar
• Verster JC, Veldhuijzen DS, Patat A, Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf 2006;1:63-71
   PubMedGoogle Scholar
• Verster JC, Roth T. Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP). Int J Gen Med 2011;4:359-71
   PubMedGoogle Scholar
• Verster JC, Volkerts ER, Olivier B, Zolpidem and traffic safety - the importance of treatment compliance. Curr Drug Saf 2007;2:220-6
   PubMedGoogle Scholar
• Hoque R and Chesson AL. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med 2009;5:471-6
   PubMed Web of Science ®Google Scholar
• Pressman MR. Sleep driving: sleepwalking variant or misuse of z-drugs? Sleep Med Rev 2011;15:285-92
   PubMed Web of Science ®Google Scholar
• Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs 2008;22:1021-36
   PubMed Web of Science ®Google Scholar
• Poceta JS. Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series. J Clin Sleep Med 2011;7:632-8
   PubMed Web of Science ®Google Scholar
• Ben-Hamou M, Marshall NS, Grunstein RR, Spontaneous adverse event reports associated with zolpidem in Australia 2001-2008. J Sleep Res 2011;20:559-68
   PubMed Web of Science ®Google Scholar
• Owen RT. Novel zolpidem formulations. Drugs Today (Barc) 2009;45:395-400
   PubMed Web of Science ®Google Scholar
• Barkin RL. Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther 2007;14:299-305
   PubMedGoogle Scholar
• Zammit G. Zolpidem extended-release: therapy for sleep induction and sleep maintenance difficulties. Expert Opin Drug Metab Toxicol 2008;4:325-31
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Legangneux E, Harmatz JS, Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 2006;46:1469-80
   PubMed Web of Science ®Google Scholar
• Weinling E, McDougall S, Andre F, Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fund Clin Pharmacol 2006;20:397-403
   PubMed Web of Science ®Google Scholar
• Roth T, Soubrane C, Titeux L, Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006;7:397-406
   PubMed Web of Science ®Google Scholar
• Krystal AD, Erman M, Zammit GK, Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008;31:79-90
   PubMed Web of Science ®Google Scholar
• Walsh JK, Soubrane C, Roth T. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry 2008;16:44-57
   PubMed Web of Science ®Google Scholar
• Fava M, Asnis GM, Shrivastava R, Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol 2009;29:222-30
   PubMed Web of Science ®Google Scholar
• Kleykamp BA, Griffiths RR, McCann UD, Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use. Exp Clin Psychopharmacol 2011;20:28-39
   PubMed Web of Science ®Google Scholar
• Staner L, Eriksson M, Cornette F, Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study. Sleep Med 2009;10:616-20
   PubMed Web of Science ®Google Scholar
• Staner C, Joly F, Jacquot N, Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia. Curr Med Res Opin 2010;26:1423-31
   PubMed Web of Science ®Google Scholar
• Staner L, Danjou P, Luthringer R. A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia. Expert Rev Neurother 2012;12:141-53
   PubMed Web of Science ®Google Scholar
• Lankford A. Sublingual zolpidem tartrate lozenge for the treatment of insomnia. Expert Rev Clin Pharmacol 2009;2:333-7
   PubMedGoogle Scholar
• Roth T, Mayleben D, Corser BC, Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate. Hum Psychopharmacol 2008;23:13-20
   PubMed Web of Science ®Google Scholar
• Roth T, Hull SG, Lankford DA, Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep 2008;31:1277-84
   PubMed Web of Science ®Google Scholar
• Sateia MJ and Nowell PD. Insomnia. Lancet 2004;364:1959-73
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Reynolds CF. Management of insomnia. N Engl J Med 1997;336:341-6
   PubMed Web of Science ®Google Scholar
• Drake CL, Roehrs T, Roth T. Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety 2003;18:163-76
   PubMed Web of Science ®Google Scholar
• Simon GE, vonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997;154:1417-23
   PubMed Web of Science ®Google Scholar
• Thase ME. Correlates and consequences of chronic insomnia. Gen Hosp Psychiatry 2005;27:100-12
   PubMed Web of Science ®Google Scholar
• Metlaine A, Leger D, Choudat D. Socioeconomic impact of insomnia in working populations. Ind Health 2005;43:11-19
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund PA, Coulouvrat C, Insomnia and the performance of US workers: results from the America insomnia survey. Sleep 2011;34:1161-71
   PubMed Web of Science ®Google Scholar
• Hulhoven R, Desager JP, Harvengt C, Lack of interaction between zolpidem and H2 antagonists, cimetidine and ranitidine. Int J Clin Pharmacol Res 1988;8:471-6
   PubMedGoogle Scholar
• Piergies AA, Sweet J, Johnson M, The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1996;34:178-83
   PubMed Web of Science ®Google Scholar
• Allard S, Sainati S, Roth-Schechter B, Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women. Drug Metab Dispos 1998;26:617-22
   PubMed Web of Science ®Google Scholar
• Saari TI, Laine K, Leino K, Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Br J Clin Pharmacol 2007;63:116-20
   PubMed Web of Science ®Google Scholar
• Luurila H, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol 1998;54:336-40
   Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther 1998;64:661-71
   PubMed Web of Science ®Google Scholar
• Vlase L, Popa A, Neag M, Effect of fluvoxamine on the pharmacokinetics of zolpidem: a two-treatment period study in healthy volunteers. Clin Exp Pharmacol Physiol 2012;39:9-12
   PubMed Web of Science ®Google Scholar
• Farkas D, Volak LP, Harmatz JS, Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin Pharmacol Ther 2009;85:644-50
   PubMed Web of Science ®Google Scholar
• Cysneiros RM, Farkas D, Harmatz JS, Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. Clin Pharmacol Ther 2007;82:54-62
   PubMed Web of Science ®Google Scholar
• Vlase L, Popa A, Neag M, Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. J Clin Pharmacol 2011;51:1233-6
   PubMed Web of Science ®Google Scholar
• Villikka K, Kivistö KT, Luurila H, Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 1997;62:629-34
   PubMed Web of Science ®Google Scholar
• Hojo Y, Echizenya M, Ohkubo T, Drug interaction between St John's wort and zolpidem in healthy subjects. J Clin Pharm Ther 2011;36:711-15
   PubMed Web of Science ®Google Scholar
• Merlotti L, Roehrs T, Koshorek G, The dose effects of zolpidem on the sleep of healthy normals. J Clin Psychopharmacol 1989;9:9-14
   PubMed Web of Science ®Google Scholar